|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.170 USD | -1.08% |
|
-3.93% | -15.94% |
| 09/07 | Evolus, Inc. Partners with Symatese to Commence Distribution of Nuceiva | CI |
| 09/07 | Evolus Partners With Symatese to Distribute Nuceiva in France | MT |
| Capitalization | 60Cr 51Cr 48Cr 45Cr 82Cr 5.14TCr 92Cr 580.36Cr 219.5Cr 2.4TCr 224.18Cr 219.55Cr 8.9TCr | P/E ratio 2025 * |
29.9x | P/E ratio 2026 * | 11.5x |
|---|---|---|---|---|---|
| Enterprise value | 68Cr 58Cr 54Cr 50Cr 93Cr 5.81TCr 103.7Cr 656.1Cr 248.14Cr 2.72TCr 253.43Cr 248.21Cr 10TCr | EV / Sales 2025 * |
2.22x | EV / Sales 2026 * | 1.76x |
| Free-Float |
79.24% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Evolus, Inc.
More recommendations
More press releases
More news
| 1 day | -1.08% | ||
| 1 week | -3.93% | ||
| Current month | +0.76% | ||
| 1 month | -6.83% | ||
| 3 months | -8.21% | ||
| 6 months | -12.54% | ||
| Current year | -15.94% |
| 1 week | 9.18 |  | 9.84 |
| 1 month | 9 | | 9.95 |
| Current year | 8.67 | | 17.12 |
| 1 year | 8.67 | | 17.82 |
| 3 years | 6.51 | | 17.82 |
| 5 years | 2.85 | | 17.82 |
| 10 years | 2.85 | | 39.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Moatazedi
CEO | Chief Executive Officer | 47 | 06/05/2018 |
Rui Avelar
CTO | Chief Tech/Sci/R&D Officer | 63 | 01/01/2014 |
Nareg Sagherian
IRC | Investor Relations Contact | - | 04/01/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Vikram Malik
CHM | Chairman | 62 | 01/01/2018 |
David Gill
BRD | Director/Board Member | 70 | 12/02/2018 |
David Moatazedi
BRD | Director/Board Member | 47 | 06/05/2018 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 0% | 293,477 M€ | -0.05% | - | |
| 0% | 9 M€ | +4.44% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.08% | -3.93% | -22.80% | -25.94% | 60Cr | ||
| +2.35% | +1.01% | -15.58% | +147.03% | 69TCr | ||
| +5.78% | +5.43% | +9.11% | -5.43% | 37TCr | ||
| +1.92% | +0.34% | +13.04% | +27.88% | 33TCr | ||
| +0.12% | -2.13% | -55.30% | +2.59% | 30TCr | ||
| +0.31% | -1.08% | -0.66% | -21.82% | 26TCr | ||
| -1.17% | -2.23% | -3.57% | +16.15% | 23TCr | ||
| -0.59% | +1.20% | -13.34% | -5.50% | 22TCr | ||
| +0.56% | -1.33% | -34.15% | -10.55% | 20TCr | ||
| +0.94% | +0.21% | -10.81% | +21.86% | 16TCr | ||
| Average | +0.93% | -0.48% | -13.40% | +14.63% | 27.65TCr | |
| Weighted average by Cap. | +1.62% | -0.70% | -11.67% | +39.09% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 35Cr 30Cr 28Cr 26Cr 48Cr 2.99TCr 53Cr 338.11Cr 127.88Cr 1.4TCr 130.6Cr 127.91Cr 5.18TCr | 46Cr 40Cr 37Cr 35Cr 64Cr 3.99TCr 71Cr 450.39Cr 170.34Cr 1.87TCr 173.97Cr 170.39Cr 6.91TCr |
| Net income | 1.97Cr 1.7Cr 1.58Cr 1.47Cr 2.71Cr 169.57Cr 3.03Cr 19Cr 7.24Cr 79Cr 7.4Cr 7.24Cr 293.6Cr | 4.75Cr 4.09Cr 3.81Cr 3.55Cr 6.52Cr 408.36Cr 7.29Cr 46Cr 17Cr 191.02Cr 18Cr 17Cr 707.05Cr |
| Net Debt | 7.8Cr 6.72Cr 6.25Cr 5.82Cr 11Cr 670.75Cr 12Cr 76Cr 29Cr 313.76Cr 29Cr 29Cr 1.16TCr | 4.9Cr 4.22Cr 3.93Cr 3.66Cr 6.72Cr 421.37Cr 7.52Cr 48Cr 18Cr 197.1Cr 18Cr 18Cr 729.57Cr |
More financial data
* Estimated data
Employees
372
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/25/16 | 9.280 $ | +0.11% | 96,565 |
| 15/25/15 | 9.270 $ | -2.52% | 13,07,543 |
| 14/25/14 | 9.510 $ | +0.32% | 6,90,942 |
| 11/25/11 | 9.480 $ | -2.57% | 8,52,343 |
| 10/25/10 | 9.730 $ | +0.72% | 5,55,686 |
Delayed Quote Nasdaq, July 16, 2025 at 08:35 pm IST
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
9.270USD
Average target price
23.57USD
Spread / Average Target
+154.28%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- EOLS Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition